溶瘤腺病毒对视网膜母细胞瘤展现出治疗潜力

2019-01-28 MedSci MedSci原创

顶尖杂志Science Translational Medicine杂志上发表的研究结果表明,病毒疗法在小鼠模型和试验性临床试验中已显示出对视网膜母细胞瘤治疗潜力。

顶尖杂志Science Translational Medicine杂志上发表的研究结果表明,溶瘤病毒疗法在小鼠模型和试验性临床试验中已显示出对视网膜母细胞瘤治疗潜力。

化疗是视网膜母细胞瘤的标准治疗方法,但是化疗可能会损伤视网膜并导致长期视力问题,甚至在某些情况下需要进行眼球摘除术。

VCN-01是利用病毒来感染并杀死携带功能失调的RB1蛋白的癌细胞,来发挥治疗作用。

新闻媒体称,虽然需要进一步开展工作,但该治疗为癌症的潜在新治疗方案奠定了基础。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1772292, encodeId=a2df1e7229206, content=<a href='/topic/show?id=c38963544cc' target=_blank style='color:#2F92EE;'>#母细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63544, encryptionId=c38963544cc, topicName=母细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b07438375157, createdName=huperzia, createdTime=Wed Nov 13 12:36:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270167, encodeId=501612e0167a3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jan 30 00:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475962, encodeId=ae9114e59621f, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Wed Jan 30 00:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359533, encodeId=722e3595336b, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 29 21:51:52 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1772292, encodeId=a2df1e7229206, content=<a href='/topic/show?id=c38963544cc' target=_blank style='color:#2F92EE;'>#母细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63544, encryptionId=c38963544cc, topicName=母细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b07438375157, createdName=huperzia, createdTime=Wed Nov 13 12:36:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270167, encodeId=501612e0167a3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jan 30 00:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475962, encodeId=ae9114e59621f, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Wed Jan 30 00:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359533, encodeId=722e3595336b, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 29 21:51:52 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
    2019-01-30 zutt
  3. [GetPortalCommentsPageByObjectIdResponse(id=1772292, encodeId=a2df1e7229206, content=<a href='/topic/show?id=c38963544cc' target=_blank style='color:#2F92EE;'>#母细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63544, encryptionId=c38963544cc, topicName=母细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b07438375157, createdName=huperzia, createdTime=Wed Nov 13 12:36:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270167, encodeId=501612e0167a3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jan 30 00:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475962, encodeId=ae9114e59621f, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Wed Jan 30 00:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359533, encodeId=722e3595336b, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 29 21:51:52 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1772292, encodeId=a2df1e7229206, content=<a href='/topic/show?id=c38963544cc' target=_blank style='color:#2F92EE;'>#母细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63544, encryptionId=c38963544cc, topicName=母细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b07438375157, createdName=huperzia, createdTime=Wed Nov 13 12:36:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270167, encodeId=501612e0167a3, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Jan 30 00:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1475962, encodeId=ae9114e59621f, content=<a href='/topic/show?id=2bcee797732' target=_blank style='color:#2F92EE;'>#细胞瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77977, encryptionId=2bcee797732, topicName=细胞瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf5e7252474, createdName=spoonycyy, createdTime=Wed Jan 30 00:36:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359533, encodeId=722e3595336b, content=学习了长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Jan 29 21:51:52 CST 2019, time=2019-01-29, status=1, ipAttribution=)]
    2019-01-29 1ddf0692m34(暂无匿称)

    学习了长知识

    0

相关资讯

Sci Transl Med:重大进展!联合使用三种策略导致癌症治疗反应率接近100%

在一项新的研究中,来自美国麻省总医院、新泽西州立大学和拉什大学医学中心的研究人员发现将三种先进的治疗恶性黑色素瘤的策略---分子靶向疗法、免疫检查点阻断和使用溶瘤病毒---结合在一起可能显着地改善治疗结果。相关研究结果发表在2018年12月12日的Science Translational Medicine期刊上,论文标题为“MEK inhibition enhances oncolytic vi

CLIN CANCER RES:溶瘤疫苗病毒GL-ONC1治疗腹膜转移癌

腹膜转移癌是常见的晚期肿瘤,通常由消化道肿瘤、妇科肿瘤或原发腹膜癌进展而来。目前的治疗策略有效性均较差,需要开发新的治疗方案。CLIN CANCER RES近期发表了一篇文章,评估腹腔内注射溶瘤疫苗病毒GL-ONC1治疗晚期腹膜转移癌患者的安全性,最大耐受剂量及抗肿瘤活性。

Cancer Res:双杀!全新溶瘤病毒问世!击溃癌细胞与肿瘤保护层!

癌症是一种非常古老的疾病,但即使在医疗技术发展得如火如荼的今日,彻底攻克癌症仍遥不可及,因而民众多畏之如虎。目前癌症治疗仍以传统手术、放疗、化疗为主,辅以靶向、免疫、细胞等疗法,但只要复发的问题一日不解决,攻克癌症就只是纸上谈兵。近日,牛津大学的研究人员开发了一种新型溶瘤病毒,实现了对癌细胞和肿瘤保护层的双杀!更重要的是,这种全新的免疫疗法有望彻底杜绝癌症复发!

Cell:溶瘤病毒联合PD-1/L1抗体,更佳拍档或是打破瓶颈的法宝丨医麦新观察

溶瘤病毒是指一大类能选择性裂解癌细胞的病毒,它能诱导多种抗肿瘤机制,一方面可以感染肿瘤细胞并引起肿瘤细胞裂解,另一方面裂解过程中释放的相关分子还能激发诱导先天性和适应性免疫反应,吸引更多免疫细胞来继续杀死残余肿瘤细胞,这使得溶瘤病毒明显不同于许多其他仅针对一种或几种免疫抑制途径的免疫疗法。此外,许多溶瘤病毒还可以容纳治疗性转基因的插入(称为“武装”的处理),增强抗肿瘤功效。

Nat Rev Cancer:溶瘤病毒能怎样协助免疫疗法?

肿瘤免疫疗法在近年来取得了一系列进展,改变了许多癌症的治疗格局。但与此同时,肿瘤免疫疗法也暴露出了作用人群不够广泛等瓶颈,限制了它的应用。为了让其发挥出更大的潜力,研发人员们正在为它寻找帮手,形成更为有效的组合疗法。而在诸多潜在的好帮手中,溶瘤病毒是最为引人关注的新疗法之一。近日,《Nature Reviews | Cancer》刊登了一篇综述,介绍了溶瘤病毒在未来免疫组合疗法中的广阔应用前景。

强生10亿美元收购BeneVir Biopharm公司推进溶瘤免疫疗法

强生旗下的杨森Janssen签署了一份最终协议,将收购一家私人控股的生物制药公司--BeneVir Biopharm,该公司一直致力于溶瘤病毒作用的免疫疗法。